The estimated Net Worth of Andrew A. F. Hack is at least $158 Milione dollars as of 8 August 2023. Andrew Hack owns over 1,500,000 units of Mersana Therapeutics Inc stock worth over $1,619,550 and over the last 8 years he sold MRSN stock worth over $156,655,000. In addition, he makes $118,120 as Independent Director at Mersana Therapeutics Inc.
Andrew has made over 32 trades of the Mersana Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 1,500,000 units of MRSN stock worth $21,585,000 on 8 August 2023.
The largest trade he's ever made was buying 3,445,667 units of Mersana Therapeutics Inc stock on 7 April 2020 worth over $20,639,545. On average, Andrew trades about 422,892 units every 47 days since 2017. As of 8 August 2023 he still owns at least 915,000 units of Mersana Therapeutics Inc stock.
You can see the complete history of Andrew Hack stock trades at the bottom of the page.
Dr. Andrew A. F. Hack M.D., Ph.D. serves as Independent Director of the Company. Since March 2019, Dr. Hack has served as a Managing Director of Bain Capital Life Sciences, a private equity fund that invests in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics, and enabling life science technology companies globally. Before joining Bain Capital, Dr. Hack was the Chief Financial Officer of Editas Medicine from July 2015 through March 2019. Previously, Dr. Hack served as a portfolio manager at Millennium Management, where he ran a healthcare hedge fund focused on biotechnology, pharmaceutical and medical device companies from May 2011 to June 2015. Prior to Millennium, Andrew was an analyst at HealthCor Management from December 2008 to May 2011. Prior to HealthCor Management, Dr. Hack was an analyst at Carlyle-Blue Wave Partners and a principal of the MPM BioEquities Fund. He started his investment career as an equity research analyst covering the biotechnology sector at Banc of America Securities after serving as Director of Life Sciences at Reify Corporation, a life science tools and drug discovery company. In addition, Dr. Hack has been a member of the Board of Directors of Allena Pharmaceuticals since June 2018, and serves as the Chair of its Audit Committee, and has been a member of the Board of Directors of Dynavax Technologies since August 2019, and serves as a member of its Audit Committee. Dr. Hack received his B.A. in biology with special honors from the University of Chicago, where he also received his M.D. and Ph.D. and was named the inaugural Frank Family Scholar. Hack’s financial background, as well as his experience in the biotechnology sector and his medical background, qualify him to serve as a member of our Board of Directors.
As the Independent Director of Mersana Therapeutics Inc, the total compensation of Andrew Hack at Mersana Therapeutics Inc is $118,120. There are 14 executives at Mersana Therapeutics Inc getting paid more, with Anna Protopapas having the highest compensation of $1,739,800.
Andrew Hack is 46, he's been the Independent Director of Mersana Therapeutics Inc since 2017. There are 17 older and 3 younger executives at Mersana Therapeutics Inc. The oldest executive at Mersana Therapeutics Inc is Lawrence Alleva, 70, who is the Independent Director.
Andrew's mailing address filed with the SEC is C/O BAIN CAPITAL LIFE SCIENCES INVESTORS, 200 CLARENDON STREET, BOSTON, MA, 02116.
Over the last 7 years, insiders at Mersana Therapeutics Inc have traded over $1,068,087 worth of Mersana Therapeutics Inc stock and bought 26,457,775 units worth $226,822,416 . The most active insiders traders include Forest Baskett, Scott D Sandell e Anthony A. Jr. Florence. On average, Mersana Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $534,621. The most recent stock trade was executed by Anna Protopapas on 13 January 2024, trading 86,958 units of MRSN stock currently worth $153,916.
mersana is rewriting the rules for immunoconjugate therapies by leveraging our fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives. our fleximer platform allows us to custom design an adc with specific properties to overcome limitations of current adc approaches and increase the drug’s chances of effectively attacking a particular cancer. we engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, mersana’s adc therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.
Mersana Therapeutics Inc executives and other stock owners filed with the SEC include: